Skip to content

The role of patient advocacy organizations in obesity treatment policy

Coverage and policy change rarely come from one person's effort. What patient advocacy organizations do, how to judge one (including its funding), and how to take part without just donating.

Updated Sep 26, 2026Evidence-backed

Your own appeal or conversation with HR can change your coverage. Changing it for everyone, through a state mandate, a Medicare policy shift, or an insurer loosening its formulary criteria, usually takes organized effort sustained over years. That's the work patient advocacy organizations do, and you can take part in it.

What patient advocacy organizations do

Groups working on obesity and metabolic health usually work on several fronts at once.

Lobbying and legislative campaigns. They meet with lawmakers, testify at hearings, and coordinate constituent outreach timed to legislative sessions. The Medicare coverage push is one long-running example.

Public comment. When an agency proposes a change to insurance, Medicare or Medicaid policy, it opens a public comment period, and advocacy groups help patients take part. More participation helps, but the number of comments isn't what decides the outcome. Agencies say the comment process is not a vote, and that one well-supported comment is often more useful to them than a thousand form letters (EPA: commenting on dockets (external link)). Congressional offices react similarly: in a Congressional Management Foundation survey, 47% of staff said they believe most identical form messages are sent without the constituent's knowledge or approval (CMF, Citizen-Centric Advocacy (external link)). A comment in your own words, with your own facts, counts for more.

Research and policy briefs. Some fund or publish data on treatment access, cost-effectiveness and disparities that policymakers and insurers cite.

Direct patient support. Many also run peer support communities and education programs, and some help people with appeals or coverage denials.

Public narrative. They work to change how the public and policymakers see obesity, as a chronic disease and not a personal failing, which affects both policy and how patients are treated in clinics. Our guide on obesity as a chronic disease vs. a lifestyle choice goes into this.

How to find and evaluate one

Look for groups that say where their money comes from, publish their policy positions and legislative activity, and offer ways to take part beyond donating. Established groups usually publish annual reports and legislative tracking, so you can see what they're working on.

Industry funding is common in this field. A 2017 analysis in the New England Journal of Medicine looked at 104 large U.S. patient-advocacy organizations and found that 86 of them (83%) reported financial support from drug, device or biotech companies (McCoy et al., 2017 (external link)). That doesn't disqualify a group, but it's worth knowing when you read its policy positions.

Two examples in this space: the Obesity Action Coalition, a patient-focused advocacy group, and The Obesity Society, a scientific and clinical professional society.

How to take part beyond donating

  • Sign up for legislative action alerts, which usually turn contacting your representative about a specific bill into a two-minute task.
  • Submit a public comment when a campaign is open. Groups usually provide a template; add your own experience instead of sending it word for word.
  • Share your story through the organization's story-collection program. These stories are often used in testimony or media outreach (see our guide on sharing your story).
  • Join or start a local chapter or community group if the organization supports one.

This article is general education, not medical, legal, or insurance advice. Coverage rules, appeal rights, and policy details vary by plan and location and change over time. Confirm specifics with your plan, prescriber, or a qualified advisor.

advocacy-organizationspolicycommunity

Was this helpful?

Common questions

Questions people often ask about this topic.

  • What do patient advocacy organizations actually do?

    They usually work on several fronts: lobbying lawmakers and testifying, helping patients take part in official public comment periods, funding or publishing research and policy briefs, running peer support and education programs, and working to change how obesity is understood. The common thread is turning individual patient experiences into organized pressure on policy that lasts.

  • How can I get involved beyond donating?

    Sign up for legislative action alerts, which usually turn contacting your representative about a specific bill into a two-minute task; submit a public comment when a campaign is open, adding your own experience to any template; share your story through the organization's story-collection program; or join a local chapter or community group if one exists.

  • How do I know if an advocacy organization is legitimate?

    Look for a group that says where its money comes from, publishes its policy positions and legislative activity, and offers ways to take part beyond donating. Industry funding is common: a 2017 NEJM analysis found 83% of 104 large U.S. patient-advocacy organizations reported support from drug, device or biotech companies. It isn't disqualifying, but it's worth knowing.

  • Can an advocacy organization help with my individual insurance denial?

    Sometimes. Many organizations run patient support programs alongside their policy work, including education and, in some cases, help with appeals or coverage denials. Their main focus is changing policy, but individual support is often part of what they offer.

  • Do organized comment campaigns carry more weight than individual comments?

    Campaigns raise participation, but agencies say the comment process is not a vote: a single well-supported comment can matter more than a thousand form letters. If you join a campaign, write the comment in your own words and include your own facts.

Evidence: For & Against

Both sides of the topic, so you can weigh the evidence yourself.

2Supporting

  • Commenting on EPA Dockets (external link)

    U.S. Environmental Protection Agency · Clinical guideline · Moderate evidence

    (2026)

    Federal agency commenter guidance: 'The comment process is not a vote – one well-supported comment is often more informative to the agency than a thousand form letters.' Same wording as the government-wide regulations.gov 'Tips for Submitting Effective Comments'.

  • Citizen-Centric Advocacy: The Untapped Power of Constituent Engagement (external link)

    Congressional Management Foundation, 2017 · Reporting · Moderate evidence

    Bradford Fitch, Kathy Goldschmidt, Nicole Folk Cooper (2017)

    Congressional staff surveys: 47% believe most identical form messages are sent without the constituent's knowledge or approval; individualized contact and sustained relationships are valued above mass form campaigns. Staff self-report.

1Mixed findings

  • Conflicts of Interest for Patient-Advocacy Organizations (external link)

    New England Journal of Medicine, 2017 · Peer-reviewed study · Strong evidence

    McCoy MS, Carniol M, Chockley K, Urwin JW, Emanuel EJ, Schmidt H (2017) · N Engl J Med

    doi:10.1056/NEJMsr1610625

    Review of 104 U.S. patient-advocacy organizations with revenues of $7.5 million or more: 86 (83%) reported financial support from drug, device or biotech companies; only one said it doesn't accept industry support; 37 had an industry executive on the board. N Engl J Med 2017;376(9):880-885.

Revision history

Last updated · 4 revisions recorded.

Show what changed
  1. v4

    Evidence sources 0 → 3

  2. v3

    Common questions 4 → 5

  3. v2

    Summary rewritten; Body revised

  4. v1

    Existing article recorded at the start of version history

Improve this page

Community notes

Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.

Loading notes…

    New submissions are currently paused. Existing approved notes remain available.

    Related guides

    • FDA's proposal to keep compounded GLP-1s off the 503B bulks list — and how to comment — In May 2026 the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B compounding bulks list, a decision that affects how compounded GLP-1s can be made. The public comment period closed July 30, 2026, and as of late September 2026 the FDA has not published a final determination. This guide explains the proposal, why it matters for access, and what you can still do.
    • The Treat and Reduce Obesity Act (H.R. 4231 / S. 1973): what it is and why it matters — TROA is the main federal bill aimed at ending Medicare's exclusion of obesity medications. It was first introduced in 2013 and has been reintroduced with bipartisan support in later Congresses, but it hasn't passed. This guide explains what it would change.
    • Sharing your story: how patient testimonials influence coverage decisions and legislation — Congressional staff say personal stories are helpful and that they rarely get them. Where your GLP-1 coverage story can be used, how to tell it so it's useful, and what to check before you share it.
    • How to find and join a GLP-1 patient advocacy or support community — Where to find GLP-1 patient communities and advocacy groups, how to tell peer support from organized advocacy, and the warning signs that a group isn't as neutral as it looks.
    • The push to get Medicare to cover GLP-1 medications for obesity — Medicare is legally barred from covering weight-loss drugs, yet it covers the same medications for diabetes or heart disease. As of September 2026, a temporary CMS demonstration called the GLP-1 Bridge lets eligible beneficiaries get certain GLP-1s for about $50 a month while the underlying exclusion stays in place. This guide explains why the gap exists, what the Bridge does and doesn't change, and how patients and advocates are pushing for a permanent fix.
    • How GLP-1 coverage mandates differ by state — A few states require some insurance plans to cover obesity treatment, including GLP-1 medications; most don't. This guide covers how state mandates work, why they skip most people with job-based insurance, and how to find out what your state requires.